BETA · Beta Drugs Ltd · Biotechnology & Drugs
Last close, 30 Oct
36.0% below 52-week high
52-week range: as of 30 Oct 2026.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Stock Condition as of 30 Oct 2026 close
Full signal detail →Chart
Fundamentals as of 15 Sep 2026 · the company's own latest record is 47 days old
Revenue (latest Q)
₹126 Cr
Revenue YoY
PAT YoY
+35.0%
Operating margin
Revenue, last 5 quarters
P/E (TTM)
P/B
10
P/S (TTM)
5.7
Sector P/E
36.3
Dividend yield
0.0%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| BETA (this stock) | 49.4 | 10 | +11.1% | +18.6% | 0.6 | 0.0% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
falling 1q
MF
Not available from data source
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
- loweconomictimes.indiatimes.com· 22 Oct 2026, 01:19 pmAshish Kacholia portfolio: Ace investor adds 3 new stocks, trims stake in 13 companies in Q2
Concalls & investor presentations
AI-generatedKey takeaway: Beta Drugs Limited (BETA) presented an overview of its operations and financial performance in its investor presentation dated July 2026. Established in 2005, the company focuses on specialty pharmaceuticals, particularly in oncology, and has expanded into IVF and dermatology. BETA reported a 5-year revenue CAGR of 27% and a 5-year PAT CAGR of 29%. The company operates three WHO-GMP certified manufacturing facilities and serves over 85% of corporate and government hospitals in India, with exports to more than 25 countries. In Q1-FY27, BETA achieved a revenue of INR 1,255 million, reflecting a 25.2% year-on-year growth. The branded oncology segment grew by 47% year-on-year, while the contract manufacturing business increased by 41%. Management highlighted a robust pipeline of new products and a strategic vision for 2030 aimed at enhancing revenue from branded products.
The presentation emphasized strong growth metrics and strategic expansion initiatives.
Sourced from an exchange-filed presentation, dated 27 Jul 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: During the Q4 FY26 earnings conference call, management highlighted that Beta Drugs Limited's net revenue increased from INR 368 crores to INR 396 crores, with gross margins rising from 52.71% to 55.52%. EBITDA grew from INR 76.97 crores to INR 86.85 crores, while net profit margin declined from 11.71% to 10.78%, impacted by extraordinary expenses. Segment-wise, branded sales grew by 20%, while export sales declined by 11% due to delayed tenders. Management announced a goal of over 50% growth in exports for FY27. The acquisition of a 66.1% stake in Nivian Lifesciences was also discussed, with management noting potential synergies. The company aims to double its sales by FY30, with a focus on oncology, exports, and new product launches. Management acknowledged challenges faced in FY26 but expressed commitment to achieving their Vision 2030.
Management reported both growth in certain segments and challenges faced in others.
Sourced from an exchange-filed transcript, dated 22 May 2026. Summary is RedixFi-generated and distinct from investment advice.
Governance disclosures
AI-generatedNo governance disclosures identified in BETA's filed documents yet.